Isocarboxazid

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instance_of gptkb:depression
gptkbp:approves gptkb:1959
gptkb:FDA
gptkbp:available_on gptkb:tablet
gptkbp:brand Marplan
gptkbp:casnumber 59-73-2
gptkbp:chemical_formula C12 H13 N3 O3
gptkbp:class hydrazine derivative
gptkbp:clinical_trial studied for PTSD
studied for anxiety disorders
studied for panic disorder
studied for social anxiety disorder
gptkbp:contraindication gptkb:pheochromocytoma
liver disease
concurrent use of certain medications
gptkbp:dosage_form 10 to 20 mg daily
gptkbp:drug_interactions SSRIs
tricyclic antidepressants
sympathomimetics
meperidine
gptkbp:duration long-term use
https://www.w3.org/2000/01/rdf-schema#label Isocarboxazid
gptkbp:invention patented
gptkbp:is_monitored_by gptkb:weight
mood
blood pressure
gptkbp:lifespan 2 to 4 hours
gptkbp:marketed_as various pharmaceutical companies
gptkbp:mechanism_of_action inhibition of monoamine oxidase
gptkbp:metabolism liver
gptkbp:premiered_on 1 to 2 weeks
gptkbp:requires requires dietary restrictions
gptkbp:research_status ongoing studies
gptkbp:route_of_administration oral
gptkbp:side_effect dizziness
insomnia
dry mouth
weight gain
orthostatic hypotension
gptkbp:storage room temperature
gptkbp:structure carboxylic acid
aromatic ring
hydrazine group
gptkbp:symptoms anxiety
headache
nausea
irritability
gptkbp:used_for treatment of depression
gptkbp:bfsParent gptkb:Sunovion_Pharmaceuticals
gptkb:Monoamine_oxidase_inhibitors
gptkbp:bfsLayer 7